[Federal Register Volume 76, Number 100 (Tuesday, May 24, 2011)]
[Notices]
[Pages 30093-30094]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-12762]
-----------------------------------------------------------------------
DEPARTMENT OF AGRICULTURE
Animal and Plant Health Inspection Service
[Docket No. APHIS-2011-0049]
Effectiveness Indications Statements in Veterinary Biologics
Labeling; Notice of Public Meeting and Request for Comments
AGENCY: Animal and Plant Health Inspection Service, USDA.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: We are issuing this notice to inform producers and users of
veterinary biological products, as well as other interested
individuals, that we will be holding a public meeting to discuss a
draft guideline (concept paper) concerning effectiveness indications
statements in veterinary biologics labeling. We are also making the
concept paper available for review and comment.
DATES: The public meeting will be held on Thursday, June 16, 2011, from
9 a.m. to 3 p.m. We will consider all comments that we receive on or
before July 25, 2011.
ADDRESSES: The public meeting will be held at the National Centers for
Animal Health, 1920 Dayton Avenue, Ames, IA. You may submit comments on
the concept paper by either of the following methods:
Federal eRulemaking Portal: Go to http://www.regulations.gov/fdmspublic/component/main?main=DocketDetail&d=APHIS-2011-0049 to submit or view comments and
to view the concept paper.
Postal Mail/Commercial Delivery: Please send one copy of
your comment to Docket No. APHIS-2011-0049, Regulatory Analysis and
Development, PPD, APHIS, Station 3A-03.8, 4700 River Road Unit 118,
Riverdale, MD 20737-1238. Please state that your comment refers to
Docket No. APHIS-2011-0049.
Reading Room: You may view the concept paper and any comments we
receive on the Regulations.gov Web site (see link above) or in our
reading room. The reading room is located in room 1141 of the USDA
South Building, 14th Street and Independence Avenue SW., Washington,
DC. Reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday,
except holidays. To be sure someone is there to help you, please call
(202) 690-2817 before coming.
FOR FURTHER INFORMATION CONTACT: Ms. Dee McVey, Center for Veterinary
Biologics, VS, APHIS, 1920 Dayton Avenue, Ames, IA 50010; phone (515)
337-6100, fax (515) 337-6120, or e-mail: [email protected].
SUPPLEMENTARY INFORMATION: The Animal and Plant Health Inspection
Service (APHIS) administers and enforces the Virus-Serum-Toxin Act (the
Act), as amended (21 U.S.C. 151-159). The regulations issued pursuant
to the Act are intended to ensure that veterinary biological products
are pure, safe, potent, and effective when used according to label
instructions. The regulations in 9 CFR part 112 prescribe requirements
for packaging and labeling veterinary biologics. The regulations in
part 112 ensure that labeling provides adequate information concerning
the expected effectiveness and safety of the product. Current APHIS
guidelines (Veterinary Services Memorandum [VSM] No. 800.202--General
Licensing Considerations: Efficacy Studies) provide examples of
statements that may be used in labeling to describe the indications for
use of a product, provided that the product has demonstrated a
specified level of performance in an efficacy study that was the basis
for issuance of the product license. VSM 800.202 specifies performance
requirements and allowable indications statements for four different
levels (tiers) of effectiveness.
In July 2009, representatives of veterinary biologics manufacturers
and the American Veterinary Medical Association met with APHIS to
discuss the Agency's current labeling guidance and to explore the
possibility of developing a single indications
[[Page 30094]]
statement that would convey clinically useful information to veterinary
practitioners and other consumers of veterinary biologics. At that
meeting, the American Veterinary Medical Association, which represents
the single largest group of consumers of veterinary biologics, informed
APHIS that its members consider labeling indications statements that
are based on the guidance provided in VSM 800.202 to be confusing and
expressed a desire for indications statements that provide insight into
the actual performance of the product, including summaries of safety
and efficacy data. On the other hand, representatives of the trade
associations representing veterinary biologics manufacturers have
remarked that their members expend significant resources on studies to
provide data to support labeling that includes indications statements
that emphasize the unique properties of their product versus that of a
competitor. They expressed concern about any change to the labeling
regulations that would deemphasize product differences or require
public disclosure of proprietary information that could compromise
manufacturers' competitive positions in the marketplace.
In response to the concerns expressed by these stakeholders, APHIS
has developed a draft policy guideline (concept paper) concerning the
wording of indications statements used in veterinary biologics
labeling. The draft guideline differs from current guidance regarding
label claims in VSM 800.202 in that a single indications statement
(e.g., ``This product has been shown to be effective for the
vaccination of healthy animals X weeks of age or older against * * *'')
would replace current indications statements that may reflect any of
four different levels of effectiveness. In addition to a standardized
indications statement, the draft guideline also provides for the public
disclosure of a summary (with confidential business information
removed) of the efficacy and safety data submitted to APHIS in support
of the issuance of the product license. The draft guideline may be
viewed on the Regulations.gov Web site (see ADDRESSES above) or
obtained from the person listed under FOR FURTHER INFORMATION CONTACT.
We are holding a public meeting to solicit input and discussion of
any issues that are pertinent to this concept. This meeting is
scheduled for Thursday, June 16, 2011. Registration information and
copies of the agenda for the meeting may be obtained from the person
listed under FOR FURTHER INFORMATON CONTACT. The public meeting will
begin at 9 a.m. and is scheduled to end at 3 p.m. but may end earlier
if all persons wishing to comment have been heard. The meeting will be
recorded, and information about obtaining a transcript will be provided
at the meeting. If you require special accommodations, such as a sign
language interpreter, please contact the person listed under FOR
FURTHER INFORMATION CONTACT.
You may also submit comments regarding the concept paper using one
of the methods described under ADDRESSES above.
Done in Washington, DC, this 18th day of May 2011.
Kevin Shea,
Acting Administrator, Animal and Plant Health Inspection Service.
[FR Doc. 2011-12762 Filed 5-23-11; 8:45 am]
BILLING CODE 3410-34-P